Status
Conditions
About
Examine the risk of cardiovascular events (cardiac arrhythmia or myocardial ischemia) or all-cause mortality in Chronic Obstructive Pulmonary Disease (COPD) patients who are new users of Olodaterol or other LABAs available for the treatment of COPD.
Full description
Purpose:
Time Perspective:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
none
65,406 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal